HU188311B - Process for producing biologically active polisaccharide concentrates and pharmaceutical compositions containing them as active agents - Google Patents
Process for producing biologically active polisaccharide concentrates and pharmaceutical compositions containing them as active agents Download PDFInfo
- Publication number
- HU188311B HU188311B HU82660A HU66082A HU188311B HU 188311 B HU188311 B HU 188311B HU 82660 A HU82660 A HU 82660A HU 66082 A HU66082 A HU 66082A HU 188311 B HU188311 B HU 188311B
- Authority
- HU
- Hungary
- Prior art keywords
- und
- polysaccharide
- priority
- water
- sie
- Prior art date
Links
- 239000012141 concentrate Substances 0.000 title claims description 63
- 238000000034 method Methods 0.000 title claims description 17
- 239000013543 active substance Substances 0.000 title description 2
- 239000008194 pharmaceutical composition Substances 0.000 title description 2
- 241000700159 Rattus Species 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims abstract description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 10
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims abstract description 10
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 10
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 10
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229930182830 galactose Natural products 0.000 claims abstract description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 6
- 239000008103 glucose Substances 0.000 claims abstract description 6
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 5
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims abstract description 5
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims abstract description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract description 5
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims abstract description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims abstract description 4
- 150000004676 glycans Chemical class 0.000 claims description 83
- 229920001282 polysaccharide Polymers 0.000 claims description 83
- 239000005017 polysaccharide Substances 0.000 claims description 83
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 23
- 239000002244 precipitate Substances 0.000 claims description 23
- 238000005119 centrifugation Methods 0.000 claims description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 17
- 238000001914 filtration Methods 0.000 claims description 16
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 16
- 241000196324 Embryophyta Species 0.000 claims description 14
- 239000006286 aqueous extract Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 235000000346 sugar Nutrition 0.000 claims description 11
- 229920001525 carrageenan Polymers 0.000 claims description 10
- 239000002537 cosmetic Substances 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 206010030113 Oedema Diseases 0.000 claims description 9
- 239000008346 aqueous phase Substances 0.000 claims description 9
- 239000000679 carrageenan Substances 0.000 claims description 9
- 229940113118 carrageenan Drugs 0.000 claims description 9
- 229960000905 indomethacin Drugs 0.000 claims description 8
- 241000699670 Mus sp. Species 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 7
- 229960002895 phenylbutazone Drugs 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 6
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000000829 suppository Substances 0.000 claims description 5
- 241000219071 Malvaceae Species 0.000 claims description 4
- 239000012736 aqueous medium Substances 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- -1 mucus Substances 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 239000011574 phosphorus Substances 0.000 claims description 4
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 claims description 4
- 150000001768 cations Chemical class 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000002808 molecular sieve Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 241000219317 Amaranthaceae Species 0.000 claims description 2
- 241000208838 Asteraceae Species 0.000 claims description 2
- 241000207923 Lamiaceae Species 0.000 claims description 2
- 241000013557 Plantaginaceae Species 0.000 claims description 2
- 235000004789 Rosa xanthina Nutrition 0.000 claims description 2
- 241000220222 Rosaceae Species 0.000 claims description 2
- 241001093501 Rutaceae Species 0.000 claims description 2
- 229920005654 Sephadex Polymers 0.000 claims description 2
- 239000012507 Sephadex™ Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 239000012452 mother liquor Substances 0.000 claims description 2
- 210000003097 mucus Anatomy 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 239000003978 infusion fluid Substances 0.000 claims 1
- 235000015110 jellies Nutrition 0.000 claims 1
- 239000008274 jelly Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 239000000344 soap Substances 0.000 claims 1
- 229940034610 toothpaste Drugs 0.000 claims 1
- 239000000606 toothpaste Substances 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract description 4
- CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 abstract 1
- 150000002256 galaktoses Chemical class 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- 235000019441 ethanol Nutrition 0.000 description 17
- 238000003756 stirring Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 235000010418 carrageenan Nutrition 0.000 description 9
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 8
- 241001312519 Trigonella Species 0.000 description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 description 6
- 239000002260 anti-inflammatory agent Substances 0.000 description 6
- 229940070641 chamomile flowers Drugs 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 235000013616 tea Nutrition 0.000 description 6
- 244000269722 Thea sinensis Species 0.000 description 5
- 240000007313 Tilia cordata Species 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 150000003180 prostaglandins Chemical class 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 210000000582 semen Anatomy 0.000 description 5
- 241000628997 Flos Species 0.000 description 4
- 240000000982 Malva neglecta Species 0.000 description 4
- 235000000060 Malva neglecta Nutrition 0.000 description 4
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000004426 flaxseed Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 244000208874 Althaea officinalis Species 0.000 description 3
- 235000006576 Althaea officinalis Nutrition 0.000 description 3
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 3
- 235000017788 Cydonia oblonga Nutrition 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 240000006240 Linum usitatissimum Species 0.000 description 3
- 235000004431 Linum usitatissimum Nutrition 0.000 description 3
- 244000042664 Matricaria chamomilla Species 0.000 description 3
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 244000250129 Trigonella foenum graecum Species 0.000 description 3
- 235000001484 Trigonella foenum graecum Nutrition 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000001035 marshmallow Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- 229940126585 therapeutic drug Drugs 0.000 description 3
- 235000001019 trigonella foenum-graecum Nutrition 0.000 description 3
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical class CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 235000001258 Cinchona calisaya Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 108010068370 Glutens Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241001547424 Kitaibela Species 0.000 description 2
- 244000090599 Plantago psyllium Species 0.000 description 2
- 235000010451 Plantago psyllium Nutrition 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000907897 Tilia Species 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
- 229910001863 barium hydroxide Inorganic materials 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000021312 gluten Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- RNVCVTLRINQCPJ-UHFFFAOYSA-N o-toluidine Chemical compound CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229960000948 quinine Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 229930189957 Bisabolol oxide Natural products 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 101100016398 Danio rerio hars gene Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010022714 Intestinal ulcer Diseases 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000208202 Linaceae Species 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241001127637 Plantago Species 0.000 description 1
- 241000842539 Rhagades Species 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 244000078534 Vaccinium myrtillus Species 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000000883 ear external Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000008124 floral development Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000321 herbal drug Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 231100000508 hormonal effect Toxicity 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000009160 phytotherapy Methods 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 150000003214 pyranose derivatives Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001562 ulcerogenic effect Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Priority Applications (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU82660A HU188311B (en) | 1982-03-04 | 1982-03-04 | Process for producing biologically active polisaccharide concentrates and pharmaceutical compositions containing them as active agents |
| FI830650A FI72735C (fi) | 1982-03-04 | 1983-02-28 | Foerfarande foer framstaellning av anti-inflammatoriska polysackarider. |
| DK104983A DK104983A (da) | 1982-03-04 | 1983-02-28 | Fremgangsmaade til fremstilling af biologisk aktive polysaccharidkoncentrater |
| PT76314A PT76314B (en) | 1982-03-04 | 1983-03-01 | Process for the preparation of biologically active polysaccharide concentrates and of pharmaceutical and cosmetic compositions containing them |
| PL1983240853A PL143397B1 (en) | 1982-03-04 | 1983-03-03 | Method of obtaining biologicaly active polysaccharide concentrates |
| NO830736A NO158101C (no) | 1982-03-04 | 1983-03-03 | Fremgangsmaate ved fremstilling av polysaccharider med antiinflammatorisk aktivitet. |
| RO83110208A RO90536A (ro) | 1982-03-04 | 1983-03-03 | Procedeu de preparare a concentratelor de polizaharide cu actiune antiinflamatoare |
| DD83248465A DD247567A7 (de) | 1982-03-04 | 1983-03-03 | Verfahren zur herstellung bon biologisch aktiven polysacchariidkonzentraten und diese enthaltenden arzneimittelpraeparaten |
| CS831515A CS258450B2 (en) | 1982-03-04 | 1983-03-03 | Method of vegetal polysaccharides winning |
| ES520334A ES8403930A1 (es) | 1982-03-04 | 1983-03-04 | Procedimiento para la preparacion de concentrados de polisacaridos de actividad biologica a partir de sustancias vegetales. |
| AT83102130T ATE35272T1 (de) | 1982-03-04 | 1983-03-04 | Polysaccharidkonzentrate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel und kosmetische praeparate. |
| GR70693A GR78464B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1982-03-04 | 1983-03-04 | |
| JP58034690A JPS58201719A (ja) | 1982-03-04 | 1983-03-04 | 生物学的に活性な多糖類コンセントレ−ト及びその物質を含む組成物の製造方法 |
| US06/472,060 US4511559A (en) | 1982-03-04 | 1983-03-04 | Biologically active polysaccharide concentrates and process for production of preparates containing such substances |
| DE8383102130T DE3377134D1 (en) | 1982-03-04 | 1983-03-04 | Polysaccharide concentrates, process for their preparation and medicinal and cosmetic compositions containing them |
| EP83102130A EP0089529B1 (de) | 1982-03-04 | 1983-03-04 | Polysaccharidkonzentrate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel und kosmetische Präparate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU82660A HU188311B (en) | 1982-03-04 | 1982-03-04 | Process for producing biologically active polisaccharide concentrates and pharmaceutical compositions containing them as active agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HU188311B true HU188311B (en) | 1986-04-28 |
Family
ID=10950710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU82660A HU188311B (en) | 1982-03-04 | 1982-03-04 | Process for producing biologically active polisaccharide concentrates and pharmaceutical compositions containing them as active agents |
Country Status (15)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6023401A (ja) * | 1983-03-09 | 1985-02-06 | Toyo Soda Mfg Co Ltd | 多糖類およびその製造法 |
| US4923697A (en) * | 1985-04-24 | 1990-05-08 | Bar-Ilan University | Antioxidant compositions and methods |
| US4857325A (en) * | 1985-04-24 | 1989-08-15 | Bar-Ilan University | Antioxidant compositions and methods |
| GB8520101D0 (en) * | 1985-08-09 | 1985-09-18 | Unilever Plc | Phase separation |
| EP0213099A3 (de) * | 1985-08-23 | 1989-07-19 | Cederroth Nordic Aktiebolag | Mittel mit antiphlogistischer, immunstimulierender und zytoprotektiver Wirkung, ihre Herstellung und pharmazeutische Verwendungen |
| DE3541945A1 (de) * | 1985-11-27 | 1987-06-04 | Lomapharm Rudolf Lohman Gmbh K | Immunstimulierend wirkende polysaccharide aus zellkulturen von echinacea purpurea (l.) moench und echinacea angustifolia, d.c. verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen |
| IL80783A0 (en) * | 1986-10-17 | 1987-02-27 | Univ Bar Ilan | Food supplements |
| FR2617848B1 (fr) * | 1987-07-10 | 1990-01-05 | Guyomarch Sa Ets | Polysaccharides extraits, notamment, de vegetaux utiles comme medicaments et additifs alimentaires |
| US4986985A (en) * | 1987-11-02 | 1991-01-22 | Bar Ilan University | Method of treating skin virus infections |
| US5268467A (en) * | 1988-05-23 | 1993-12-07 | Verbiscar Anthony J | Immunomodulatory polysaccharide fractions from Astragalus plants |
| JP2764433B2 (ja) * | 1989-05-12 | 1998-06-11 | 花王株式会社 | 自己免疫疾患治療剤 |
| US5714164A (en) * | 1991-02-28 | 1998-02-03 | Parfums Christian Dior | Method for treatment of allergic disorders and cosmetic compositions using cucurbitine |
| WO1994001082A1 (en) * | 1992-07-14 | 1994-01-20 | Bozo Tasevski | Bozjo skin treatment mixture |
| US5679375A (en) * | 1995-06-07 | 1997-10-21 | C.V. Therapeuctics | Method of treating ulcers with sulfated polysaccharides |
| US5864034A (en) * | 1995-07-11 | 1999-01-26 | Shin-Etsu Chemical Co., Ltd. | Process for production of saline-solution soluble xanthan gum |
| JPH09175982A (ja) * | 1995-12-28 | 1997-07-08 | Nikka Uisukii Kk | 化粧品 |
| EP1155104A2 (en) | 1999-02-10 | 2001-11-21 | Eastman Chemical Company | Corn fiber for the production of advanced chemicals and materials |
| WO2002003999A1 (en) * | 2000-07-10 | 2002-01-17 | The University Of Missisippi | High molecular weight polysaccharide fraction from aloe vera with immunostimulatory activity |
| KR100831408B1 (ko) * | 2000-07-10 | 2008-05-21 | 더 유니버시티 오브 미시시피 | 미세조류로부터 얻은 유효 면역자극제 |
| RU2177793C1 (ru) * | 2000-07-26 | 2002-01-10 | Дроздова Ирина Леонидовна | Способ получения суммы полисахаридов, обладающей противовоспалительной активностью |
| US20020061339A1 (en) * | 2000-09-28 | 2002-05-23 | Martin Stogniew | Compositions and methods for use of extracts of rutaceae plants |
| RU2206333C1 (ru) * | 2002-07-22 | 2003-06-20 | Институт общей и экспериментальной биологии СО РАН | Способ получения средства, обладающего противовоспалительной активностью |
| RU2232774C1 (ru) * | 2002-12-04 | 2004-07-20 | Курский государственный медицинский университет | Способ получения водорастворимых полисахаридов |
| US20060084629A1 (en) * | 2004-10-15 | 2006-04-20 | Alvin Needleman | Immune system activating formula composed of selected long chain polysaccharides from natural sources |
| EP2543340A1 (en) * | 2006-05-19 | 2013-01-09 | Trustees Of Boston University | Novel hydrophilic polymers as medical lubricants and gels |
| WO2008129457A1 (en) * | 2007-04-18 | 2008-10-30 | Firmenich Sa | Process for preparing sweet juice extract |
| CN115010823B (zh) * | 2022-06-16 | 2023-03-24 | 佳木斯大学 | 一种调节肠道菌群的车前子多糖及其制备方法与应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE876305C (de) * | 1951-11-13 | 1953-05-11 | Ver Flussspatgruben G M B H | Verfahren zur Gewinnung therapeutisch wirksamer Pflanzenpraeparate |
| US2871235A (en) * | 1952-08-29 | 1959-01-27 | Jilovice Vladimir Jan Hlous De | Process for obtaining polysaccharide material from plants of the genus cecropia |
| GB878430A (en) * | 1958-10-15 | 1961-09-27 | Ciba Ltd | New polysaccharide material from sassafras plants and process for obtaining it |
| US3227616A (en) * | 1961-07-03 | 1966-01-04 | Warner Lambert Pharmaceutical | Emulsions of cactus plant extract |
| FR2426M (fr) * | 1962-06-15 | 1964-03-31 | Andre Beaune | Médicament pour le traitement externe des prurits, des dermatoses, des réactions allergiques cutanées et des syndromes inflammatoires en général. |
| US3374222A (en) * | 1965-07-06 | 1968-03-19 | Weyerhaeuser Co | Separating levoglucosan and carbohydrate derived acids from aqueous mixtures containing the same by treatment with metal compounds |
| US4119435A (en) * | 1976-07-30 | 1978-10-10 | Takeda Chemical Industries, Ltd. | Process of preparing soybean polysaccharides |
| ZA786132B (en) * | 1977-11-23 | 1979-12-27 | Roussel Uclaf | New gastric reflux suppressant pharmaceutical compositions |
| JPS5943929B2 (ja) * | 1979-08-13 | 1984-10-25 | サッポロビール株式会社 | 多糖体ｒｂｓ物質，その製法およびそれを有効成分とする抗腫瘍性剤 |
-
1982
- 1982-03-04 HU HU82660A patent/HU188311B/hu not_active IP Right Cessation
-
1983
- 1983-02-28 FI FI830650A patent/FI72735C/fi not_active IP Right Cessation
- 1983-02-28 DK DK104983A patent/DK104983A/da not_active Application Discontinuation
- 1983-03-01 PT PT76314A patent/PT76314B/pt unknown
- 1983-03-03 RO RO83110208A patent/RO90536A/ro unknown
- 1983-03-03 PL PL1983240853A patent/PL143397B1/pl unknown
- 1983-03-03 DD DD83248465A patent/DD247567A7/de not_active IP Right Cessation
- 1983-03-03 CS CS831515A patent/CS258450B2/cs unknown
- 1983-03-03 NO NO830736A patent/NO158101C/no unknown
- 1983-03-04 GR GR70693A patent/GR78464B/el unknown
- 1983-03-04 DE DE8383102130T patent/DE3377134D1/de not_active Expired
- 1983-03-04 ES ES520334A patent/ES8403930A1/es not_active Expired
- 1983-03-04 JP JP58034690A patent/JPS58201719A/ja active Pending
- 1983-03-04 US US06/472,060 patent/US4511559A/en not_active Expired - Fee Related
- 1983-03-04 EP EP83102130A patent/EP0089529B1/de not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| PT76314B (en) | 1985-11-25 |
| NO158101C (no) | 1988-07-13 |
| PL143397B1 (en) | 1988-02-29 |
| GR78464B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1984-09-27 |
| EP0089529B1 (de) | 1988-06-22 |
| EP0089529A3 (en) | 1984-10-17 |
| FI72735B (fi) | 1987-03-31 |
| EP0089529A2 (de) | 1983-09-28 |
| US4511559A (en) | 1985-04-16 |
| FI830650L (fi) | 1983-09-05 |
| ES520334A0 (es) | 1984-04-16 |
| PT76314A (en) | 1983-04-01 |
| DK104983D0 (da) | 1983-02-28 |
| JPS58201719A (ja) | 1983-11-24 |
| DD247567A7 (de) | 1987-07-15 |
| CS258450B2 (en) | 1988-08-16 |
| NO830736L (no) | 1983-09-05 |
| NO158101B (no) | 1988-04-05 |
| DK104983A (da) | 1983-09-05 |
| ES8403930A1 (es) | 1984-04-16 |
| RO90536A (ro) | 1986-10-30 |
| DE3377134D1 (en) | 1988-07-28 |
| FI72735C (fi) | 1987-07-10 |
| PL240853A1 (en) | 1986-02-11 |
| FI830650A0 (fi) | 1983-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU188311B (en) | Process for producing biologically active polisaccharide concentrates and pharmaceutical compositions containing them as active agents | |
| US5110803A (en) | Plant polysaccharide fractions inducing prolactin in mammals | |
| US4855284A (en) | Calcium and magnesium complexes of phytohemagglutinin-polyheteroglycans, their preparation and pharmaceutical formulations | |
| JPS60214741A (ja) | 血糖降下剤 | |
| EP4039332A1 (en) | Method of extraction and enrichment of monoglycosylated flavonoids from chrysanthellum indicum for the treatment of inflammatory-based polyarthritic disorders, for use in cosmetic, nutraceutical and medical devices and pharmaceutical applications | |
| CN109678981A (zh) | 一种红花多糖的制备方法、产品及应用 | |
| KR0172568B1 (ko) | 프로폴리스 추출정제물의 분말 및 그 수용성액 | |
| JP2002193850A (ja) | 高純度リコペンの製造方法及び用途 | |
| JPH09208480A (ja) | サブスタンスｐ拮抗剤 | |
| EP3437648A1 (en) | Method for producing nepodin-rich extract of rumex plant and nepodin-rich extract of rumex plant | |
| CN114886914A (zh) | 缓解口腔溃疡的组合物及其制备方法和应用 | |
| CN113995798A (zh) | 黑果枸杞花青素提取物及冻干粉的制备方法和在抗痛风性关节炎和降尿酸产品中的应用 | |
| KR0124969B1 (ko) | 백삼박으로부터 산성 다당체의 제조방법 | |
| JP3222661B2 (ja) | 抗腫瘍剤 | |
| US6800304B2 (en) | Anti-ulcer pharmaceutical composition and the preparation thereof | |
| KR940001730B1 (ko) | 괄루근으로부터 생체활성다당의 제조방법 | |
| JPH06113791A (ja) | ウーロン茎茶抽出物を配合した健康食品および医薬品 | |
| HU190569B (en) | Process for producing inflammation inhibiting active substance | |
| CN114601853A (zh) | 一种银杏叶提取物的制备方法 | |
| CN111603509A (zh) | 一种富含二氢杨梅素的枳椇子提取物制备方法 | |
| JPS59116226A (ja) | イネ科植物青汁源血圧降下剤 | |
| JPS6084301A (ja) | 多糖体、その製造方法、及び該多糖体を有効成分とする抗腫瘍剤 | |
| JPS6318961B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JPS6153328B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| WO2020056735A1 (zh) | 提高产物中丙二酰基人参皂苷含量的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HU90 | Patent valid on 900628 | ||
| HMM4 | Cancellation of final prot. due to non-payment of fee |